Evidence map›Paper›PMID 36615487›Full record

ArticleMolecules (Basel, Switzerland)2022

Radiochemical Synthesis of 4-[

Viktor A Il'in, Elena V Pyzhik, Anton B Balakhonov, Maksim A Kiryushin, Evgeniya V Shcherbatova, Andrey A Kuznetsov, Pavel A Kostin, Andrey V Golovin, Vladimir A Korshun, Vladimir A Brylev and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Viktor A Il'inBurdenko National Medical Research Center of Neurosurgery, Ministry of Health of the Russian Federation, 125047 Moscow, Russia.
Elena V PyzhikBurdenko National Medical Research Center of Neurosurgery, Ministry of Health of the Russian Federation, 125047 Moscow, Russia.
Anton B BalakhonovBurdenko National Medical Research Center of Neurosurgery, Ministry of Health of the Russian Federation, 125047 Moscow, Russia.
Maksim A KiryushinBurdenko National Medical Research Center of Neurosurgery, Ministry of Health of the Russian Federation, 125047 Moscow, Russia.
Evgeniya V ShcherbatovaBurdenko National Medical Research Center of Neurosurgery, Ministry of Health of the Russian Federation, 125047 Moscow, Russia.
Andrey A KuznetsovBurdenko National Medical Research Center of Neurosurgery, Ministry of Health of the Russian Federation, 125047 Moscow, Russia.
Pavel A KostinBurdenko National Medical Research Center of Neurosurgery, Ministry of Health of the Russian Federation, 125047 Moscow, Russia.
Andrey V GolovinChemistry Department, Lomonosov Moscow State University, 119991 Moscow, Russia.ORCID 0000-0002-8908-4268
Vladimir A KorshunShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.ORCID 0000-0001-9436-6561
Vladimir A BrylevShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
Kseniya A SapozhnikovaShemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
Alexey M KopylovChemistry Department, Lomonosov Moscow State University, 119991 Moscow, Russia.ORCID 0000-0003-0962-8905
Galina V PavlovaBurdenko National Medical Research Center of Neurosurgery, Ministry of Health of the Russian Federation, 125047 Moscow, Russia.ORCID 0000-0002-6885-6601
Igor N ProninBurdenko National Medical Research Center of Neurosurgery, Ministry of Health of the Russian Federation, 125047 Moscow, Russia.
Ministry of Health of the Russian Federation · RUInstitute of Bioorganic Chemistry · RULomonosov Moscow State University · RUSechenov University · RU

Funding

Ministry of Science and Higher Education of the Russian Federation No. 075-15-2020-809 (ext. number 13.1902.21.0030).
6 · The paper itself

Abstract

Central nervous system tumors related to gliomas are of neuroectodermal origin and cover about 30% of all primary brain tumors. Glioma is not susceptible to any therapy and surgical attack remains one of the main approaches to its treatment. Preoperative tumor imaging methods, such as positron emission tomography (PET), are currently used to distinguish malignant tissue to increase the accuracy of glioma removal. However, PET is lacking a specific visualization of cells possessing certain molecular markers. Here, we report an application of aptamers to enhancing specificity in imaging tumor cells bearing the epidermal growth factor receptor (EGFR). Glioblastoma is characterized by increased EGFR expression, as well as mutations of this receptor associated with active division, migration, and adhesion of tumor cells. Since 2021, EGFR has been included into the WHO classification of gliomas as a molecular genetic marker. To obtain conjugates of aptamers GR20 and GOL1-specific to EGFR, a 4-[

Indexed as

GlioblastomaGliomaAnimalsErbB ReceptorsFluorine RadioisotopesOligonucleotidesPositron-Emission TomographyRadiopharmaceuticalsErbB ReceptorsFluorine RadioisotopesOligonucleotidesRadiopharmaceuticalsCuAACEGFRiodonium ylidesoligonucleotidesPET imaging

Identifiers

PMID36615487
PMCPMC9821934
OpenAlexW4313360641

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.